Phase 4
Completed N=10
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
Immunosuppression · Stem Cell Transplant · Bone Marrow Transplant
Source: ClinicalTrials.gov NCT04041219 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Median Tacrolimus Sublingual Trough Level — 11.3 ng/mL
◆ Published Evidence
Not yet cited
0citations
Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study.
Summary
Researchers are trying to learn more about using sublingual (absorption under the tongue) tacrolimus in blood and marrow transplant patients.
Linked Publications
-
Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Median Tacrolimus Sublingual Trough Level |
11.3 | — |
| SECONDARY Median Sublingual (SL) to Oral (PO) Ratio |
1.02 | — |
Eligibility Criteria
Inclusion Criteria
- Individuals will be identified from within the adult allogeneic BMT program at Mayo Clinic in Rochester, Minnesota
- Adults prescribed tacrolimus for treatment or prevention of Graft Versus Host Disease (GVHD)
Exclusion Criteria
- Vulnerable populations
- Patients with contraindications to tacrolimus, inclusive of hypersensitivity, history of posterior reversible encephalopathy syndrome or calcineurin-inhibitor induced thrombotic microangiopathy
- Lacking the capacity to consent in English and declining to participate in research
Data sourced from ClinicalTrials.gov (NCT04041219) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.